Every 10-Q that RADNOSTIX INC (INIS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow INIS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INIS filings page.
Radnostix Inc. reported weaker results for the quarter and six months ended June 30, 2026. Sale of product fell to $2,671,785 for the quarter and $5,050,709 year‑to‑date, both down 27% from 2025, driven mainly by Theranostics and Cobalt segments.
Quarterly gross profit declined to $1,359,235 (51% margin) and net loss widened to $881,997, with six‑month net loss at $2,230,083. Operating cash flow shifted to an outflow of $686,000. Results were heavily impacted by two voluntary Theranostics product recalls and a temporary shutdown of cobalt‑60 hot cell operations for gasket rehabilitation. Calibration & Reference Products showed modest quarterly growth, and Cobalt margins improved due to lower waste costs. The company ended the period with $1,196,492 in cash and equivalents, $2,715,519 including restricted cash, total assets of $16,646,173, and stockholders’ equity of $1,892,257. Management believes cash, operations, financing options, and potential asset monetization can fund operations for the next twelve months.
Radnostix Inc. reported weaker results for the quarter ended March 31, 2026. Sale of product fell to $2,378,924 from $3,238,900, a 27% drop, driven by lower Theranostics, Cobalt, and Calibration & Reference segment revenue.
Net loss widened sharply to $1,348,086 from $112,694 as gross margin compressed to 48% from 63% and operating expenses rose 17% to $2,460,980. Results were hurt by two voluntary recalls in Theranostics, a cobalt production shutdown for hot-cell rehabilitation, and continued isotope supply constraints.
Cash and cash equivalents were $1,347,394 and total cash, cash equivalents, and restricted cash were $2,852,931. Management expects existing cash, operations, and potential financing to fund the next 12 months but notes dependence on key customers, suppliers, and ongoing access to capital.
International Isotopes Inc. (INIS) reported Q3 2025 results with sale of product of $3,277,816 and a net loss of $203,601. For the nine months ended September 30, 2025, sale of product was $10,172,036 and net loss was $477,080. Gross margin held near 59% in Q3 as operating expenses declined 7% year over year.
The company advanced its planned divestiture of the Fluorine Products and de‑conversion assets, noting total cash consideration of $12.5 million if the deal closes by the Outside Date of March 31, 2026. On September 30, 2025, INIS and the buyer submitted an application to the NRC to transfer the license; closing remains subject to financing and regulatory approvals.
Theranostics revenue fell on a temporary supplier outage and partial account loss, while Calibration & Reference grew; management cites an additional approved supplier from September. Cash and cash equivalents were $1,651,548 with restricted cash of $1,477,685. INIS disclosed an FDA inspection in April resulting in an OAI; corrective actions have been submitted and manufacturing continues pending reinspection.